Regeneron Pharmaceuticals, Inc. (BIT:1REGN)

Market Cap	57.98B
Revenue (ttm)	12.14B
Net Income (ttm)	3.90B
Shares Out	n/a
EPS (ttm)	35.45
PE Ratio	14.86
Forward PE	14.08
Dividend	2.38 (0.42%)
Ex-Dividend Date	Aug 14, 2025

Volume	41
Average Volume	35
Open	566.40
Previous Close	572.20
Day's Range	565.80 - 568.80
52-Week Range	418.00 - 778.00
Beta	n/a
RSI	71.91
Earnings Date	Oct 28, 2025

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq...

• Industry: Pharmaceutical Preparations
• Founded: 1988
• Employees: 15,106
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1REGN

Financial Performance

In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.

Financial numbers in USD